title: [Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma].
abstract: Traditionally, during the follow-up and in order to receive 131 I therapy, patients with differentiated thyroid carcinoma (DTC) have to withdraw from using thyroid hormone. The hypothyroidism induced by hormone withdrawal can negatively affect the quality-of-life (QOL) of DTC patients. Without the hormone withdrawal, recombinant human thyroid-stimulating hormone-aided management of DTC patients can effectively obviate the consequences of hypothyroidism. This review will focus on the clinical application of recombinant human thyroid-stimulating hormone (rhTSH) in the management of DTC patients.
authors: Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Bin
authors: B
authors: Liu
authors: Anren
authors: A
authors: Kuang
mesh_terms: D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D013954:Thyroglobulin / Q000097:blood; D013963:Thyroid Hormones / Q000008:administration & dosage*; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy*; D057073:Thyrotropin Alfa / Q000008:administration & dosage*
chemical_list: D007457:Iodine Radioisotopes; D013963:Thyroid Hormones; D057073:Thyrotropin Alfa; D013954:Thyroglobulin